​Respiratory diagnostics for healthcare providers

 

Since many respiratory infections share common symptoms, it can be difficult to determine which pathogens may be present. NEXT provides a set of testing options for respiratory testing to help diagnose and treat respiratory pathogens. Contact NEXT for full list of testing options. Below are several available tests:

​

• COVID-19 Testing

  • NEXT is pleased to offer COVID-19 PCR testing​ 

  • The SARS-CoV-2 assay is a real-time RT PCR (rRT-PCR) assays for the in vitro qualitative detection of 2019-Novel Coronavirus (2019-nCoV) in respiratory specimens intended for the presumptive detection of nucleic acid from the SARS-CoV-2 in nasal pharyngeal swabs taken from individuals suspected of COVID-19. Testing is limited to laboratories that are Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratories.

• SARS-CoV-2 Total Antibody Testing

  • NEXT is pleased to offer a comprehensive CoV-2 antibody test platform. In our testing scheme, the “Platelia” SARS-CoV-2 ELISA reveals the presence of antibodies directed against the CoV-2 nucleocapsid protein.  A positive test result indicates that you have been or are currently infected with covid 19 (within the past 12 months).  Our Anti-Spike Receptor Binding Domain (RBD) ELISA reveals the presence of antibodies to the RBD of the CoV2 spike protein. These antibodies may arise from covid 19 infection, but just as importantly, these antibodies arise as a consequence of vaccination with any of the currently approved covid 19 vaccines.  Antibodies to the spike protein RBD are so-called neutralizing antibodies because these antibodies are critical for blocking the uptake of the virus into cells.  The cPASS™ SARS-CoV-2 Neutralizing Antibody Functional assay reveals the presence of antibodies to the Wuhan, alpha, beta, and delta virus variants which are detected in the spike protein RBD ELISA that possess functionality in preventing binding of the spike protein to its cellular receptor, angiotensin converting enzyme-2 (ACE2).  The higher the titer determined in the spike protein ELISA, the higher the concentration of neutralizing antibodies.  Lastly, we implemented and validated a novel cPASS assay which is specific for neutralizing antibodies of the omicron variant.

  • The Platelia assay was commercialized by Bio Rad Inc and has received Emergency Use Authorization from the United States Food and Drug Administration (FDA).  The Spike Protein ELISA has not received EUA or been approved for use by the FDA. Both assays have been validated at NEXT under CLIA and GLP guidelines). 

• Flu Testing

  • Next's Reverse Transcription-Polymerase Chain Reaction (RT-PCR) can identify the presence of influenza viral RNA in respiratory specimens with very high sensitivity and specificity. Our molecular assays are able to detect and discriminate between infections with influenza A and B viruses.

• Respiratory Syncytial Virus (RSV) Lab Test: RSV PCR Testing. ​

  • ​RSV is a common respiratory virus that typically causes mild, cold-like symptoms in most people, but can be severe, particularly in infants, young children, and the elderly. Our PCR test is both sensitive and specific for RSV and fast results can be critical in treatment of this infection. 

​